U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322965) titled 'Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma' on March 25, 2025.
Brief Summary: This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.
This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial...